FDA cited Apollo Care for insanitary conditions and quality failures in sterile compounded drugs, including a sterility-assurance recall.
What happened
FDA inspected Apollo Care's Columbia, Missouri facility from March 10 to March 27, 2025, and issued a Form FDA 483 listing inspection observations on March 27, 2025. FDA found that sterile drug products were prepared under insanitary conditions and with current good manufacturing practice (CGMP) violations, including cleaning near bulk drug solution, microbial recoveries on operator gowning, foreign particles, and hard-to-clean surfaces. The firm recalled Lot AC-016878 of Fentanyl 500mcg (2mcg/mL) and Ropivacaine HCl 250mg (0.1%) in 0.9% Sodium Chloride Injection on April 15, 2025, due to lack of sterility assurance.
What FDA found
Operators sprayed cleaning agents on a mop head near a loosely foil-covered beaker of non-sterile bulk drug solution during area cleaning, risking contamination.
FDCA § 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The firm approved and distributed drug products made in an aseptic area after 1 CFU microbial recoveries on operator gowning gloves or sleeves, without adequate product evaluation and corrective action.
FDCA § 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]White fiber-like particles and debris were found on the floor of the ISO lab and hallway/anteroom after cleaning.
FDCA § 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]Production areas and equipment included textured wall panels and other surfaces that were difficult to clean or visibly dirty/rusty, which can harbor contamination and generate particles.
21 CFR 211.67(a)The firm did not establish and follow appropriate written procedures to prevent microbiological contamination of sterile drug products, including validation of aseptic and sterilization processes.
21 CFR 211.113(b)The aseptic processing areas lacked adequate systems for maintaining equipment used to control aseptic conditions.
21 CFR 211.42(c)(10)(vi)
What FDA wants
Within 15 working days of receipt, Apollo Care must notify FDA in writing of the specific steps taken to address the violations, with an explanation and supporting documentation for each step. If it cannot fully address the matter in that time, it must state the reason for delay and the time within which it will do so.
Who should pay attention
- hospitals and clinics using compounded sterile injectables
- pharmacies and providers buying from outsourcing facilities
- suppliers and contractors to sterile compounders
This is a summary. Read the original letter on fda.gov.